Cargando…

Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets

SARS-CoV-2 virions are composed of structural proteins, but during virus infection, an additional 30 proteins could be expressed according to putative open reading frames (ORFs) of the viral genome. Some of these additional proteins modulate cellular processes through direct interactions, their trun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hachim, Asmaa, Kavian, Niloufar, Valkenburg, Sophie A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376662/ https://www.ncbi.nlm.nih.gov/pubmed/34464844 http://dx.doi.org/10.1016/j.coviro.2021.08.006

Ejemplares similares

Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses
por: Kavian, Niloufar, et al.
Publicado: (2021)

The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in children
por: Hachim, Asmaa, et al.
Publicado: (2021)

Vaccination with ADCC activating HA peptide epitopes provides 1 partial protection from influenza infection
por: Kavian, Niloufar, et al.
Publicado: (2020)

Postmortem Stability of SARS-CoV-2 in Mouse Lung Tissue
por: Valkenburg, Sophie A., et al.
Publicado: (2021)

SARS-CoV-2 accessory proteins reveal distinct serological signatures in children
por: Hachim, Asmaa, et al.
Publicado: (2022)

Author Correction: ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
por: Hachim, Asmaa, et al.
Publicado: (2020)

Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain
por: Wu, Chao, et al.
Publicado: (2020)

Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain
por: Wu, Chao, et al.
Publicado: (2021)

T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants
por: Nguyen, Thi H. O., et al.
Publicado: (2021)

Domain-specific biochemical and serological characterization of SARS-CoV-2 nucleocapsid protein
por: Wu, Chao, et al.
Publicado: (2021)

SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
por: Cohen, Carolyn A, et al.
Publicado: (2021)

SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
por: Cohen, Carolyn A., et al.
Publicado: (2021)

Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults
por: Kavian, Niloufar, et al.
Publicado: (2020)

Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020
por: Chan, Paul K.S., et al.
Publicado: (2020)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

The landscape of antibody binding in SARS-CoV-2 infection
por: Heffron, Anna S., et al.
Publicado: (2021)

The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development
por: Hajissa, Khalid, et al.
Publicado: (2022)

Landscape and Selection of Vaccine Epitopes in SARS-CoV-2
por: Smith, Christof C., et al.
Publicado: (2020)

Landscape and selection of vaccine epitopes in SARS-CoV-2
por: Smith, Christof C., et al.
Publicado: (2021)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Energy landscape of the SARS-CoV-2 reveals extensive conformational heterogeneity
por: Mashayekhi, Ghoncheh, et al.
Publicado: (2022)

Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape
por: Turakhia, Yatish, et al.
Publicado: (2022)

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
por: Wheatley, Adam K., et al.
Publicado: (2021)

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
por: Lau, Jonathan J., et al.
Publicado: (2023)

SARS‐CoV‐2 vaccinations can trigger polyradiculitis
por: Finsterer, Josef, et al.
Publicado: (2022)

The Mutational Landscape of SARS-CoV-2
por: Saldivar-Espinoza, Bryan, et al.
Publicado: (2023)

SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
por: Duan, Li-Jun, et al.
Publicado: (2022)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Antibodies and Vaccines Target RBD of SARS-CoV-2
por: Min, Long, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Diagnostic Properties of Three SARS-CoV-2 Antibody Tests
por: Basgalupp, Suelen, et al.
Publicado: (2021)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
por: Yue, Lei, et al.
Publicado: (2021)

Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins
por: Li, Yang, et al.
Publicado: (2021)

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
por: Liu, Yubin, et al.
Publicado: (2023)

The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
por: Moulana, Alief, et al.
Publicado: (2023)

Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
por: Ogura, Wataru, et al.
Publicado: (2022)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

Functional landscape of SARS-CoV-2 cellular restriction
por: Martin-Sancho, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o6lihqit9ia18sg4u3nvqi2lr5